RU2016140338A - Азаспиро производные в качестве антагонистов trpm8 - Google Patents
Азаспиро производные в качестве антагонистов trpm8 Download PDFInfo
- Publication number
- RU2016140338A RU2016140338A RU2016140338A RU2016140338A RU2016140338A RU 2016140338 A RU2016140338 A RU 2016140338A RU 2016140338 A RU2016140338 A RU 2016140338A RU 2016140338 A RU2016140338 A RU 2016140338A RU 2016140338 A RU2016140338 A RU 2016140338A
- Authority
- RU
- Russia
- Prior art keywords
- difluoro
- diazaspiro
- decan
- dione
- oxoethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (162)
1. Соединение следующей формулы (I)
[Хим. 1]
в которой
A обозначает арил и гетероарил;
B обозначает арил и гетероарил;
L независимо выбран из группы, состоящей из химической связи, кислорода, серы, -NR4-, -(CRCRD)t-, -O(CRCRD)t-, -(CRCRD)tO-, -N(R4)(CRCRD)t-, -(CRCRD)tN(R4)-, -N(R4)(CRCRD)tO- и -O(CRCRD)tN(R4)-
X независимо выбран из группы, состоящей из -CH2-, кислорода, серы и NH;
RA и RB независимо выбраны из группы, состоящей из;
(1) водорода, (2) галогена, (3) (C1-C10)алкила, (4) (C3-C10)циклоалкила и (5) (C1-C10)галогеналкила; или RA и RB могут образовывать оксогруппу (=O); или RA и RB могут образовывать 3-8-членное кольцо, которое может содержать один или несколько гетероатомов, независимо выбранных из кислорода, серы и азота; и указанное кольцо необязательно замещено 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидрокси, (4) (C1-C10)алкила, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси и (8) (C1-C10)галогеналкокси;
RC и RD независимо выбраны из группы, состоящей из (1) водорода, (2) галогена, (3) (C1-C10)алкила, (4) (C3-C10)циклоалкила и (5) (C1-C10)галогеналкила; или RC и RD могут образовывать 3-8-членное кольцо, которое может содержать один или несколько гетероатомов, независимо выбранных из кислорода, серы и азота; и указанное кольцо необязательно замещено 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидрокси, (4) (C1-C10)алкила, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси и (8) (C1-C10)галогеналкокси;
R1 независимо выбран из группы, состоящей из (1) водорода, (2) галогена, (3) амино, (4) циано, (5) гидроксила, (6) (C1-C10)алкила, (7) (C3-C10)циклоалкила, (8) (C1-C10)галогеналкила, (9) (C1-C10)алкокси и (10) (C1-C10)галогеналкокси; два R1 на одном и том же атоме углерода или на разных атомах углерода могут образовывать 3-8-членное кольцо, которое может содержать атом, выбранный из кислорода, серы и азота; и указанное кольцо необязательно замещено 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидрокси, (4) (C1-C10)алкила, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси и (8) (C1-C10)галогеналкокси;
R2 независимо выбран из группы, состоящей из (1) водорода, (2) галогена, (3) амино, (4) -NH(C1-C6)алкила, (5) -N[(C1-C6)алкил]2, в котором алкилы являются одинаковыми или разными, (6) циано, (7) гидроксила, (8) нитро, (9) (C1-C6)алкилтио, (10) (C1-C10)алкила, (11) (C3-C10)циклоалкила, (12) (C1-C10)алкокси, (13) (C1-C10)галогеналкила и (14) (C1-C10)галогеналкокси;
R3 независимо выбран из группы, состоящей из (1) водорода, (2) галогена, (3) циано, (4) нитро, (5) гидроксила, (6) (C1-C6)алкилтио, (7) (C1-C6)алкилсульфинила, (8) (C1-C6)алкилсульфонила, (9) -NR5R6, (10) -C(=O)NR5R6, (11) три(C1-C6)алкилсилила, (12) (C1-C10)алкила, (13) (C3-C10)циклоалкила, (14) (C1-C6)алкокси(C0-C6)алкила, (15) (C3-C10)циклоалкокси, (16) -C(=O)(C1-C6)алкила, (17) -C(=O)O(C1-C6)алкила и (18) -C(=O)ОH; причем указанный (C1-C10)алкил, (C3-C10)циклоалкил, (C1-C6)алкокси(C0-C6)алкил и (C3-C10)циклоалкокси необязательно замещены 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидроксила, (4) циано, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси, (8) (C1-C10)галогеналкокси и (9) -NR6R5;
причем R5 и R6, вместе с атомом азота, к которому они присоединены, могут образовывать 3-10-членное кольцо, которое может содержать атом, выбранный из кислорода, серы и азота; и указанное кольцо необязательно замещено 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидроксила, (4) (C1-C10)алкила, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси и (8) (C1-C10)галогеналкокси;
R4, R5 и R6 независимо выбраны из группы, состоящей из (1) водорода, (2) (C1-C10)алкила, (3) (C3-C10)циклоалкила, (4) (C1-C10)галогеналкила, (5) гидроксил(C1-C10)алкила, (6) (C1-C10)алкокси(C1-C10)алкила, (7) H2N-(C1-C10)алкила, (8) [(C1-C10)алкил]NH-(C1-C10)алкила, (9) [(C1-C10)алкил]2N-(C1-C10)алкила, (10) (C1-C10)алкилкарбонила и (11) (C1-C10)алкилсульфонила;
p=1, 2, 3 или 4;
q=1, 2, 3 или 4; когда q составляет два или больше, чем два, R1 являются одинаковыми или разными,
r=1, 2, 3 или 4; когда r сосотавляет два или больше, чем два, R2 являются одинаковыми или разными,
s=1, 2, 3, 4, 5, 6 или 7; когда s составляет два или больше, чем два, R3 являются одинаковыми или разными,
t=1, 2 или 3; когда t составляет два или больше, чем два, RC и RD являются одинаковыми или разными,
или его фармацевтически приемлемая соль или пролекарство.
2. Соединение по п.1, в котором
R1 независимо выбран из группы, состоящей из (2) галогена, (3) амино, (4) циано, (5) гидроксила, (8) (C1-C10)галогеналкила, (9) (C1-C10)алкокси и (10) (C1-C10)галогеналкокси; два R1 на одном и том же атоме углерода или на разных атомах углерода могут образовывать 3-8-членное кольцо, которое может содержать атом, выбранный из кислорода, серы и азота; и указанное кольцо необязательно замещено 1-6 заместителями, независимо выбранными из (1) водорода, (2) галогена, (3) гидрокси, (4) (C1-C10)алкила, (5) (C3-C10)циклоалкила, (6) (C1-C10)галогеналкила, (7) (C1-C10)алкокси и (8) (C1-C10)галогеналкокси.
3. Соединение по п.1, в котором
R1 независимо выбран из группы, состоящей из (2) галогена, (3) амино, (4) циано, (5) гидроксила, (8) (C1-C10)галогеналкила, (9) (C1-C10)алкокси и (10) (C1-C10)галогеналкокси.
4. Соединение по п.1, в котором
R1 независимо обозначает (2) галоген.
5. Соединение по любому из пп. 1-4, в котором
A обозначает 6-членный арил или 5-6-членный гетероарил
или его фармацевтически приемлемая соль или пролекарство.
6. Соединение по любому из пп. 1-5, в котором
A независимо выбран из группы, состоящей из бензола, пиридина, пиридазина, пиразина, пиримидина, триазина, тиофена, фурана, пиррола, имидазола, пиразола, тиазола, изотиазола, оксазола, изоксазола и триазола.
или его фармацевтически приемлемая соль или пролекарство.
7. Соединение, выбранное из группы, состоящей из следующих соединений:
3-(2-(2,5-диметил-1-(5-метилизоксазол-3-ил)-1H-пиррол-3-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2,5-диметил-1-фенил-1H-имидазол-4-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
6-(4-(2-(2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)пиколинонитрил;
3-(2-(1-(3-хлорфенил)-2,5-диметил-1H-имидазол-4-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(1-(3-фторфенил)-2,5-диметил-1H-имидазол-4-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(1,4-диметил-5-фенил-1H-пиразол-3-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(6-метилпиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
6-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)пиколинонитрил;
8,8-дифтор-3-(2-(2ʹ-(гидроксиметил)-[1,1ʹ-бифенил]-4-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-метилпиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2,5-диметил-1-фенил-1H-имидазол-4-ил)-2-оксоэтил)-8,8-дифтор-1-окса-3-азаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(2-(гидроксиметил)пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(4-(гидроксиметил)пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2,5-диметил-1-(5-метилизоксазол-3-ил)-1H-пиррол-3-ил)-2-оксоэтил)-8,8-дифтор-1-окса-3-азаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(2-(гидроксиметил)фенил)-4-метилтиофен-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(3-(гидроксиметил)пиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(1,4-диметил-5-фенил-1H-пиразол-3-ил)-2-оксоэтил)-8,8-дифтор-1-окса-3-азаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(4-метилпиридазин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)пиразин-2-карбонитрил;
3-(2-(1,4-диметил-5-фенил-1H-пиррол-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-(гидроксиметил)пиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(6-(метил(пиридин-2-ил)амино)пиридин-3-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)пиколинонитрил;
8,8-дифтор-3-(2-оксо-2-(4-(хинолин-8-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-индол-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(хинолин-2-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(изохинолин-8-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(изохинолин-1-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(фуро[3,2-c]пиридин-4-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(6-(метил(пиридин-2-ил)амино)пиридин-3-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(6-(метил(фенил)амино)пиридин-3-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-фторпиридин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)изоникотинонитрил;
8,8-дифтор-3-(2-(4-(2-метоксипиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(4-метоксипиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(2-оксоиндолин-4-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-пирроло[3,2-c]пиридин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-пирроло[2,3-b]пиридин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(3-хлорпиридин-2-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(2-метил-1H-бензо[d]имидазол-1-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-индазол-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(6-(1H-индазол-4-ил)пиридин-3-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-бензо[d]имидазол-1-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(5-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-1,3-диметил-1H-пиррол-2-ил)бензонитрил;
3-(2-(4-(1H-пирроло[2,3-c]пиридин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(3-фтор-4-(хинолин-8-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(5-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-1-метил-1H-пиррол-2-ил)бензонитрил;
3-(5-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-3-метилтиофен-2-ил)бензонитрил;
8,8-дифтор-3-(2-(4-(2-(2-гидроксиэтокси)пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(3-фторфенил)-1,4-диметил-1H-пиррол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(5-(3-хлорфенил)-1,4-диметил-1H-пиррол-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(5-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-1,3-диметил-1H-пиррол-2-ил)бензамид;
8,8-дифтор-3-(2-(5-(2-фторфенил)-1,4-диметил-1H-пиррол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-пиразолo[3,4-b]пиридин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-пиразолo[4,3-c]пиридин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-индазол-1-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(3-фторфенил)-1-метил-1H-имидазол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(2-метил-3H-имидазо-[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(пиридин-2-илокси)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(5-(3,5-дифторфенил)-1,4-диметил-1H-пиррол-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(2ʹ-метил-[3,3ʹ-бипиридин]-6-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(1H-пиразолo[3,4-d]пиримидин-4-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(6-(1H-пирроло[2,3-c]пиридин-4-ил)пиридин-3-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-(2-гидроксиэтокси)пиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(фталазин-1-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(3H-имидазо[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-4-метилтиазол-5-ил)бензонитрил;
3-(2-(1,4-диметил-5-фенил-1H-имидазол 2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(3-фторфенил)-1,4-диметил-1H-имидазол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-1,4-диметил-1H-имидазол-5-ил)бензонитрил;
8,8-дифтор-3-(2-(5-(изохинолин-8-ил)-1,4-диметил-1H-имидазол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(2-(гидроксиметил)фенил)-1,4-диметил-1H-имидазол-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(2-(гидроксиметил)-1H-бензо[d]имидазол-1-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(3-фторфенил)-1,4-диметил-1H-пиррол-3-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-1,3-диметил-1H-пиррол-2-ил)бензонитрил;
3-(2-(5-(1H-бензо[d]имидазол-1-ил)пиразин-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(2,7-нафтиридин-1-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(2-оксо-2,3-дигидро-1H-бензо[d]имидазол-1-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(2-(гидроксиметил)фенил)пиразин-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(4-метоксипиридин-3-ил)пиразин-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(5-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-2,4-диметилтиофен-3-ил)бензамид;
3-(2-(5-(3,5-дифторфенил)-1,4-диметил-1H-имидазол-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(пиридазин-3-илокси)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(2-оксо-1H-имидазо[4,5-b]пиридин-3(2H)-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(5-(3,5-дифторфенил)-4-метилтиазол-2-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
4ʹ-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-2ʹ-метокси-[1,1ʹ-бифенил]-2-карбонитрил;
2-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенокси)никотинонитрил;
3-(2-(4-((3-хлорпиридин-2-ил)окси)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-(гидроксиметил)пиридин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(2ʹ-(аминометил)-[1,1ʹ-бифенил]-4-ил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(6-(хинолин-8-ил)пиридин-3-ил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(2-метилпиридин-3-ил)пиразин-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(2,7-нафтиридин-1-ил)фенил)-2-оксоэтил)-8,8-дифтор-1-окса-3-азаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)-2-метил-3H-имидазо[4,5-b]пиридин-5-карбонитрил;
8,8-дифтор-3-(2-оксо-2-(4-(2-оксобензо[d]оксазол-3(2H)-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(2,5-диметил-3H-имидазо-[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(5-(2-метил-1H-бензо[d]имидазол-1-ил)пиразин-2-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(2-метокси-5-метил-3H-имидазо-[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(5-метил-2-(трифторметил)-3H-имидазо[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(2-(4-(2-(дифторметил)-5-метил-3H-имидазо[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(5-метил-2-оксо-1H-имидазо[4,5-b]пиридин-3(2H)-ил)фенил)-2-оксоэтил)1,3-диазаспиро[4.5]декан-2,4-дион;
6-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенокси)пиколинонитрил;
8,8-дифтор-3-(2-(4-(5-метил-3H-имидазо-[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(3-метоксипиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-3-фторфенил)пиразин-2-карбонитрил;
8,8-дифтор-3-(2-(4-(имидазо[1,2-b]пиридазин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(2ʹ-(2-гидроксиэтил)-[1,1ʹ-бифенил]-4-ил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
2-(4ʹ-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)-[1,1ʹ-бифенил]-2-ил)ацетонитрил;
3-(2-(4-(1H-имидазо[4,5-b]пиразин-1-ил)фенил)-2-оксоэтил)-8,8-дифтор-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(4-(4-метилпиридазин-3-ил)фенил)-2-оксоэтил)-1-окса-3-азаспиро[4.5]декан-2,4-дион;
3-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенокси)пиридазин-4-карбонитрил;
8,8-дифтор-3-(2-(4-(2-(гидроксиметил)-5-метил-3H-имидазо[4,5-b]пиридин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-оксо-2-(4-(пиразолo[1,5-a]пиримидин-3-ил)фенил)этил)-1,3-диазаспиро[4.5]декан-2,4-дион;
4-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)никотинонитрил;
8,8-дифтор-3-(2-(2-фтор-4-(4-метилпиридазин-3-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион;
8,8-дифтор-3-(2-(2-фтор-4-(3-(гидроксиметил)пиразин-2-ил)фенил)-2-оксоэтил)-1,3-диазаспиро[4.5]декан-2,4-дион; и
2-(4-(2-(8,8-дифтор-2,4-диоксо-1,3-диазаспиро[4.5]декан-3-ил)ацетил)фенил)никотинонитрил
или его фармацевтически приемлемая соль или пролекарство.
8. Применение соединения по любому из пп. 1-7 или его фармацевтически приемлемой соли или пролекарства для получения лекарственного средства для лечения состояния или нарушения, опосредуемого антагонистической активностью по отношению к рецептору TRPM8.
9. Применение по п.8, в котором состояние или нарушение представляет собой одно или более воспалительных, болевых и урологических заболеваний или нарушений, включая хроническую боль; нейропатическую боль, включая холодовую аллодинию и диабетическую невропатию; послеоперационную боль; остеоартрит; ревматоидную подагрическую боль; боль при раке; невралгию; невропатии; повышенную чувствительность к боли; гиперчувствительность дентина; повреждение нерва; мигрень; кластерные и тензионные головные боли; ишемию; синдром раздраженной толстой кишки; синдром Рейно; нейродегенерацию; фибромиалгию; инсульт; зуд; психические расстройства, включая тревогу и депрессию; воспалительные заболевания, включая астму, хроническое обструктивное заболевание легких, заболевание дыхательных путей, включая COPD, легочную гипертензию; тревогу, включая другие обусловленные стрессом нарушения; и урологические заболевания или нарушения, включая гиперактивность детрузора или гиперактивный мочевой пузырь, недержание мочи, нейрогенную гиперактивность детрузора или гиперфлексию детрузора, идиопатическую гиперактивность детрузора или нестабильность детрузора, доброкачественную гипертрофию предстательной железы и симптомы нижних мочевыводящих путей; и их комбинации.
10. Способ лечения состояния или нарушения, опосредуемого антагонистической активностью по отношению к рецептору TRPM8, у млекопитающего, включая человека, который включает введение млекопитающему, нуждающемуся в таком лечении, терапевтически эффективного количества соединения по любому из пп. 1-7 или его фармацевтически приемлемой соли или пролекарства.
11. Способ по п.10, в котором состояние или нарушение представляет собой одно или более воспалительных, болевых и урологических заболеваний или нарушений, включая хроническую боль; нейропатическую боль, включая холодовую аллодинию и диабетическую невропатию; послеоперационную боль; остеоартрит; ревматоидную подагрическую боль; боль при раке; невралгию; невропатии; повышенную чувствительность к боли; гиперчувствительность дентина; повреждение нерва; мигрень; кластерные и тензионные головные боли; ишемию; синдром раздраженной толстой кишки; синдром Рейно; нейродегенерацию; фибромиалгию; инсульт; зуд; психические расстройства, включая тревогу и депрессию; воспалительные заболевания, включая астму, хроническое обструктивное заболевание легких, заболевание дыхательных путей, включая COPD, легочную гипертензию; тревогу, включая другие обусловленные стрессом нарушения; и урологические заболевания или нарушения, включая гиперактивность детрузора или гиперактивный мочевой пузырь, недержание мочи, нейрогенную гиперактивность детрузора или гиперфлексию детрузора, идиопатическую гиперактивность детрузора или нестабильность детрузора, доброкачественную гипертрофию предстательной железы и симптомы нижних мочевыводящих путей; и их комбинации.
12. Фармацевтическая композиция, включающая соединение или его фармацевтически приемлемую соль или пролекарство по любому из пп. 1-7 и фармацевтически приемлемый носитель.
13. Фармацевтическая композиция по п.12, дополнительно включающая другое фармакологически активное средство.
14. Соединение по любому из пп. 1-7 или его фармацевтически приемлемая соль или пролекарство для применения в лечении состояния или нарушения, опосредуемого антагонистической активностью по отношению к рецептору TRPM8.
15. Способ получения фармацевтической композиции, включающий смешивание соединения по любому из пп. 1-7, или его фармацевтически приемлемой соли или пролекарства и фармацевтически приемлемого носителя или эксципиента.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461953521P | 2014-03-14 | 2014-03-14 | |
US61/953,521 | 2014-03-14 | ||
PCT/JP2015/001454 WO2015136947A1 (en) | 2014-03-14 | 2015-03-16 | Azaspiro derivatives as trpm8 antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016140338A true RU2016140338A (ru) | 2018-04-19 |
RU2016140338A3 RU2016140338A3 (ru) | 2018-10-24 |
RU2683309C2 RU2683309C2 (ru) | 2019-03-28 |
Family
ID=54071402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016140338A RU2683309C2 (ru) | 2014-03-14 | 2015-03-16 | Азаспиропроизводные в качестве антагонистов trpm8 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10093678B2 (ru) |
EP (1) | EP3116858B1 (ru) |
JP (1) | JP6643545B2 (ru) |
KR (1) | KR102425400B1 (ru) |
CN (1) | CN106103416B (ru) |
CA (1) | CA2940621C (ru) |
ES (1) | ES2850999T3 (ru) |
HK (1) | HK1226064A1 (ru) |
MX (1) | MX2016011632A (ru) |
RU (1) | RU2683309C2 (ru) |
TW (1) | TWI674257B (ru) |
WO (1) | WO2015136947A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013011188B1 (pt) | 2010-11-05 | 2022-01-04 | Senomyx, Inc | Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto |
ES2877356T3 (es) | 2014-01-27 | 2021-11-16 | Molecular Templates Inc | Epítopo de MHC de clase I que suministra polipéptidos |
EP3660035A1 (en) | 2015-05-30 | 2020-06-03 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
CR20180102A (es) | 2015-08-14 | 2018-05-11 | Bayer Cropscience Ag | Derivados de triazol, sus intermediarios y su utilización como fungicidas |
US20180305341A1 (en) * | 2015-09-11 | 2018-10-25 | Raqualia Pharma Inc. | Imidazolinone derivatives as trpm8 antagonists |
EP3356356B1 (en) * | 2015-10-01 | 2021-05-26 | Firmenich Incorporated | Compounds useful as modulators of trpm8 |
MX2021001091A (es) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. |
RS60855B1 (sr) * | 2016-01-13 | 2020-10-30 | Gruenenthal Gmbh | Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
BR112018073700A2 (pt) * | 2016-05-19 | 2019-02-26 | Glaxosmithkline Intellectual Property (No. | antagonista trpv4 |
KR102580647B1 (ko) | 2016-12-07 | 2023-09-20 | 몰레큘러 템플레이츠, 인코퍼레이션. | 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자 |
CN110536695B (zh) | 2017-01-25 | 2024-05-10 | 分子模板公司 | 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子 |
US20200045967A1 (en) * | 2017-02-08 | 2020-02-13 | Bayer Cropscience Aktiengesellschaft | Novel triazole derivatives |
US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
EP3661509A4 (en) | 2017-08-04 | 2021-01-13 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE |
JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
JP7323200B2 (ja) | 2018-04-17 | 2023-08-08 | モレキュラー テンプレーツ,インク. | 脱免疫化志賀毒素aサブユニット足場を含むher2ターゲティング分子 |
JP7421507B2 (ja) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
CA3128500A1 (en) * | 2019-02-01 | 2020-08-06 | Marshall University Research Corporation | Transient receptor potential melastatin 8 (trpm8) antagonists and related methods |
KR20210135241A (ko) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
KR20220092509A (ko) | 2019-10-01 | 2022-07-01 | 엠피리언 뉴로사이언스, 인크. | 트립타민 발현을 조절하는 균류의 유전자 공학 |
CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
CN111518015A (zh) * | 2020-05-20 | 2020-08-11 | 上海合全药物研发有限公司 | 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739336A (en) | 1995-06-23 | 1998-04-14 | Syntex (U.S.A.) Inc. | 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives |
WO2005044978A2 (en) | 2003-07-15 | 2005-05-19 | Washington University | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation |
US20080214654A1 (en) | 2004-10-13 | 2008-09-04 | Bayer Healthcare Ag | Substituted Benzyloxy-Phenylmethylamide Derivatives |
WO2006040103A1 (en) | 2004-10-13 | 2006-04-20 | Bayer Healthcare Ag | Use of cold menthol receptor modulators for the treatment of respiratory disorders |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
EP2061775A2 (en) * | 2006-09-13 | 2009-05-27 | Astra Zeneca AB | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
US8232409B2 (en) * | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
WO2010103381A1 (en) * | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Spirocyclic piperidine derivatives as trpm 8 modulators |
KR101386679B1 (ko) | 2009-07-10 | 2014-04-17 | 주식회사 녹십자 | 신규한 아릴피페라진-함유 이미다졸 4-카복사마이드 유도체 및 이를 포함하는 약학 조성물 |
TW201209056A (en) | 2010-05-25 | 2012-03-01 | Taisho Pharmaceutical Co Ltd | Novel heterocyclic compound or salt thereof |
US9487507B2 (en) | 2011-06-17 | 2016-11-08 | Glaxosmithkline Intellectual Property (No. 2) Limited | TRPV4 antagonists |
WO2014025651A1 (en) | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
ES2717941T3 (es) | 2013-02-19 | 2019-06-26 | Senomyx Inc | Compuestos útiles como moduladores de TRPM8 |
AU2014221659B2 (en) | 2013-03-01 | 2018-12-20 | Clio, Inc. | Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury |
-
2015
- 2015-03-16 WO PCT/JP2015/001454 patent/WO2015136947A1/en active Application Filing
- 2015-03-16 MX MX2016011632A patent/MX2016011632A/es unknown
- 2015-03-16 CN CN201580013708.3A patent/CN106103416B/zh active Active
- 2015-03-16 US US15/125,615 patent/US10093678B2/en active Active
- 2015-03-16 TW TW104108412A patent/TWI674257B/zh active
- 2015-03-16 JP JP2016557355A patent/JP6643545B2/ja active Active
- 2015-03-16 CA CA2940621A patent/CA2940621C/en active Active
- 2015-03-16 KR KR1020167027045A patent/KR102425400B1/ko active IP Right Grant
- 2015-03-16 EP EP15760744.1A patent/EP3116858B1/en active Active
- 2015-03-16 RU RU2016140338A patent/RU2683309C2/ru active
- 2015-03-16 ES ES15760744T patent/ES2850999T3/es active Active
-
2016
- 2016-12-16 HK HK16114375A patent/HK1226064A1/zh unknown
-
2018
- 2018-07-31 US US16/050,514 patent/US20180339993A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2683309C2 (ru) | 2019-03-28 |
CN106103416B (zh) | 2021-03-02 |
RU2016140338A3 (ru) | 2018-10-24 |
EP3116858A1 (en) | 2017-01-18 |
CA2940621A1 (en) | 2015-09-17 |
US10093678B2 (en) | 2018-10-09 |
HK1226064A1 (zh) | 2017-09-22 |
US20170002016A1 (en) | 2017-01-05 |
EP3116858A4 (en) | 2017-11-22 |
EP3116858B1 (en) | 2020-11-11 |
MX2016011632A (es) | 2016-12-12 |
WO2015136947A1 (en) | 2015-09-17 |
US20180339993A1 (en) | 2018-11-29 |
JP2017507981A (ja) | 2017-03-23 |
KR102425400B1 (ko) | 2022-07-26 |
CA2940621C (en) | 2022-03-15 |
JP6643545B2 (ja) | 2020-02-12 |
CN106103416A (zh) | 2016-11-09 |
ES2850999T3 (es) | 2021-09-02 |
TW201623250A (zh) | 2016-07-01 |
KR20160132041A (ko) | 2016-11-16 |
TWI674257B (zh) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
US20230234958A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
JP2020514267A5 (ru) | ||
HRP20200962T1 (hr) | Novi spojevi | |
JP5911638B2 (ja) | ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用 | |
AU2011240808B2 (en) | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases | |
JP2017530960A5 (ru) | ||
AU2010249380B2 (en) | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors | |
KR101954044B1 (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
US20200172546A1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
HRP20151232T1 (hr) | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora | |
HRP20160744T2 (hr) | Heterocikličke tvari i njihova uporaba kao modulatora receptora tirozin kinaza tipa iii | |
JP2019535689A5 (ru) | ||
JP2013522354A5 (ru) | ||
RU2015129538A (ru) | Замещенные имидазопиридины в качестве ингибиторов hdm2 | |
JP2016500671A5 (ru) | ||
JP2012532931A5 (ru) | ||
JP2014528482A5 (ru) | ||
JP2013523884A5 (ru) | ||
HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
JP2012528828A5 (ru) | ||
JP2018505903A5 (ru) | ||
JP2015537010A5 (ru) | ||
JP2022502424A (ja) | モノアシルグリセロールリパーゼ調節因子 |